TIO Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- TIO, when overexpressed, dominantly inhibits male meiotic cytokinesis in a dose-dependent manner. This inhibition may involve direct binding to a component of the canonical NACK-PQR cytokinesis signaling pathway. PMID: 24146312
Q&A
Here’s a structured FAQ collection for researchers investigating TIO antibodies in translational immuno-oncology, synthesized from peer-reviewed literature and patents:
Advanced Research Questions
How to resolve contradictions in TIO antibody efficacy across preclinical models?
Discrepancies often arise from tumor microenvironment (TME) heterogeneity. Strategies include:
-
TME Profiling: Single-cell RNA sequencing to identify stromal cell interactions .
-
Dosage Optimization: Pharmacokinetic modeling to align antibody half-life with tumor growth rates .
-
Control Experiments: Compare isotype antibodies and genetic knockouts (e.g., CRISPR-edited antigen-negative tumors) .
What mechanisms underlie tumor resistance to TIO antibodies, and how are they investigated?
Resistance pathways include antigen loss, immune exclusion, and suppressive cytokine upregulation. Research methodologies:
-
Functional Screens: CRISPR-Cas9 libraries to identify resistance genes .
-
Multiplex Imaging: Spatial analysis of antibody penetration in tumor cores vs. margins .
-
Biomarker Correlation: Link PD-L1/CD8+ T cell ratios to antibody response .
Methodological Challenges
How to validate TIO antibody specificity while minimizing cross-reactivity?
-
Cross-Species Testing: Validate in humanized murine models (e.g., human XCR1 knock-in) .
-
Off-Target Screening: Phage display libraries to assess binding to unrelated epitopes .
-
Computational Modeling: Molecular docking simulations to predict paratope-epitope interactions .
